NO.1 PHARMACY(SH:600833)2023-10-27 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥437,563,712.09, a decrease of 47.38% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was ¥11,671,181.38, down 71.79% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥2,769,963.09, a decline of 93.30% compared to the previous year[5]. - The basic and diluted earnings per share for Q3 2023 were both ¥0.0524, reflecting a decrease of 71.75% from the same period last year[6]. - Total revenue for the first three quarters of 2023 was CNY 1,335,807,678.27, a decrease of 24.9% compared to CNY 1,779,159,404.97 in the same period of 2022[18]. - Operating profit for the first three quarters of 2023 was CNY 47,887,098.54, a decline of 51.1% from CNY 97,852,098.88 in the previous year[18]. - The net profit for Q3 2023 was ¥57,500,776.14, a decrease of 22.9% compared to ¥74,535,052.53 in Q3 2022[19]. - The total comprehensive income for Q3 2023 was ¥91,881,587.91, slightly up from ¥91,367,846.48 in the same period last year[19]. - The basic and diluted earnings per share for Q3 2023 were both ¥0.2578, down from ¥0.3341 in Q3 2022, reflecting a decline of 22.8%[19]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥1,863,599,619.24, representing an 8.61% decrease from the end of the previous year[6]. - Total assets as of September 30, 2023, amounted to CNY 1,863,599,619.24, down from CNY 2,039,102,174.03 at the end of 2022[14]. - Total liabilities as of September 30, 2023, were CNY 856,541,789.87, a decrease from CNY 1,080,424,094.90 at the end of 2022[15]. - The company's equity attributable to shareholders increased to CNY 1,000,050,513.48 from CNY 951,670,763.24 at the end of 2022, marking a growth of 5.1%[15]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥245,917,000.02, a significant increase of 356.15% compared to the same period last year[6]. - Cash flow from operating activities for the first nine months of 2023 was ¥245,917,000.02, significantly up from ¥53,910,883.57 in the same period of 2022[22]. - Cash inflow from investment activities in the first nine months of 2023 was ¥206,291,901.57, compared to ¥103,583,825.29 in the same period last year, indicating a 99.3% increase[22]. - The net cash flow from investment activities for the first nine months of 2023 was -¥174,781,281.30, an improvement from -¥223,352,425.61 in the same period of 2022[24]. - The net cash flow from financing activities for the first nine months of 2023 was -¥409,148,534.55, compared to a positive cash flow of ¥446,598,556.88 in the same period last year[24]. - The cash and cash equivalents at the end of Q3 2023 were ¥167,069,914.29, down from ¥528,269,679.09 at the end of Q3 2022[24]. Shareholder Information - The top shareholder, Bailian Group Co., Ltd., holds 44.95% of the shares, totaling 100,274,734 shares[10]. - The total number of ordinary shareholders at the end of the reporting period was 27,592[10]. Inventory and Receivables - Cash and cash equivalents decreased to CNY 170,964,735.37 from CNY 504,932,742.28 at the end of 2022, representing a decline of 66.2%[13]. - Inventory as of September 30, 2023, was CNY 287,756,825.39, down 14.0% from CNY 334,753,732.46 at the end of 2022[13]. - Accounts receivable increased slightly to CNY 241,565,290.31 from CNY 237,999,101.33 at the end of 2022, reflecting a growth of 1.1%[13].